Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 446 across all filing types
Latest filing 2022-10-26 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于益方生物科技（上海）股份有限公司使用自筹资金支付募投项目部分款项后续以募集资金等额置换的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the use of self-raised funds to pay for part of the investment projects of Yifang Biotechnology (Shanghai) Co., Ltd., and the subsequent replacement of these funds with raised funds. It references regulatory approvals, fundraising details, board and supervisory committee approvals, and compliance with relevant laws and regulations. The document is not a financial report itself but a regulatory compliance and verification statement related to fundraising and fund usage. It does not contain financial statements or earnings data, nor is it a simple announcement of a report. It is a regulatory filing related to fundraising and compliance, fitting best under the category of Regulatory Filings (RNS). The document length is under 5,000 characters, but it contains substantive regulatory content rather than just an announcement or certification, so it is not an RPA or purely a certification. Therefore, the best classification is Regulatory Filings (RNS).
2022-10-26 Chinese
益方生物2022年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 年第三季度报告' which translates to '2022 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the third quarter of 2022. The document is over 11,000 characters long, indicating it is a full report rather than a brief announcement. The content includes unaudited financial statements and management assurances about the accuracy of the quarterly report. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data and analysis. Therefore, the document should be classified as an Interim / Quarterly Report (IR). Q3 2022
2022-10-26 Chinese
益方生物科技（上海）股份有限公司独立董事关于公司第一届董事会2022年第七次会议相关议案的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors regarding a specific board meeting resolution about the use of self-raised funds and subsequent replacement with raised funds. It discusses compliance with laws and company articles but does not contain financial statements or detailed financial data. The document is short (729 characters) and appears to be a formal opinion or certification related to board decisions rather than a full report or announcement of financial results. It is not an Annual Report, Interim Report, or Earnings Release. It is not a regulatory filing announcing a report publication but rather an opinion on a board matter. Therefore, it fits best under Regulatory Filings (RNS) as a formal compliance-related document that does not fit other categories.
2022-10-26 Chinese
益方生物关于使用自筹资金支付募投项目部分款项后续以募集资金等额置换的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the use of self-raised funds to pay for part of a fundraising investment project, with subsequent replacement by equivalent raised funds. It details the approval by the board and supervisory committee, references regulatory approvals from the China Securities Regulatory Commission, and explains the operational process and compliance with relevant regulations. The document does not contain financial statements or detailed financial performance data but is a disclosure about the company's capital usage and fundraising fund management. It is not a full annual or interim report, audit report, or earnings release. It is also not a proxy, voting result, or management change announcement. The document is a regulatory announcement about capital fund usage and replacement, fitting best under Regulatory Filings (RNS). The document length is under 5,000 characters, and it is a detailed announcement rather than a report publication notice, so RPA is not appropriate. Therefore, the classification is Regulatory Filings (RNS).
2022-10-26 Chinese
益方生物第一届监事会2022年第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the supervisory board meeting resolutions of Yifang Bio-Technology (Shanghai) Co., Ltd. It includes the approval of the use of self-raised funds and the approval of the company's 2022 third quarter report. The document states that the detailed third quarter report is published separately on the Shanghai Stock Exchange website, indicating this document is not the report itself but an announcement of the meeting resolutions and references to other filings. The document length is short (1114 characters), and it does not contain actual financial statements or detailed financial data, only the meeting resolutions and voting results. Therefore, it is not the interim/quarterly report itself but an announcement related to the supervisory board meeting and resolutions. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories more specifically.
2022-10-26 Chinese
益方生物2022年第一次临时股东大会法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, attendance, and voting procedures of a company's 2022 first extraordinary general meeting (临时股东大会). It details the legality and validity of the meeting's procedures and voting results. The document does not contain financial statements or management discussion of financial results, nor is it a report of voting results alone. It is a legal opinion related to a shareholders meeting, which is typically associated with governance or meeting procedural matters. However, it is not a direct announcement of voting results (DVA) because it focuses on the legal opinion on the meeting's procedures and validity rather than just the voting outcomes. It is also not a proxy solicitation or AGM information document. Given the nature of the document as a legal opinion on the shareholders meeting, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory or compliance documents that do not fit other categories. The document length is 4833 characters, which is substantive and not a brief announcement. Therefore, the classification is RNS with high confidence.
2022-09-21 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.